Last reviewed · How we verify
Octagam 5%
At a glance
| Generic name | Octagam 5% |
|---|---|
| Sponsor | Octapharma |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome (PHASE2)
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (PHASE2)
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (PHASE2)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Add-on Intravenous Immunoglobulins in Early Myositis (PHASE2, PHASE3)
- Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octagam 5% CI brief — competitive landscape report
- Octagam 5% updates RSS · CI watch RSS
- Octapharma portfolio CI